Tobin W Juvenal, Chief Commercial Officer of Castle Biosciences Inc (NASDAQ:CSTL), filed a Form 4 on October 30, 2026, disclosing two open-market sales of common stock totaling 6,578 shares executed on October 28, 2026, under a Rule 10b5-1 plan.

Key Highlights

  • First sale: 1,237 shares disposed of at a weighted-average price of $35.577, with individual trade prices ranging from $35.050 to $35.833.
  • Second sale: 5,341 shares disposed of at a weighted-average price of $36.619, with individual trade prices ranging from $36.085 to $36.890.
  • Combined shares sold: 6,578 shares on October 28, 2026.
  • Remaining direct ownership: 38,853 shares of common stock following both transactions.
  • 10b5-1 plan: Both sales were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 28, 2026.
  • Transaction codes: Both transactions are coded "S" (open-market sale) and were executed in multiple trades.

Juvenal's October 28 Share Sales Under Pre-Arranged Trading Plan

According to the filing, Tobin W Juvenal, identified as Chief Commercial Officer of Castle Biosciences Inc, sold a total of 6,578 shares of Castle Biosciences common stock on October 28, 2026. Both disposals are attributed to a Rule 10b5-1 plan the reporting person adopted on May 28, 2026, meaning the sales were arranged in advance under a pre-set written plan.

The first transaction involved 1,237 shares disposed of at a weighted-average sale price of $35.577 per share. The filing notes that this transaction was executed across multiple trades at prices ranging from $35.050 to $35.833, inclusive. Following that transaction, beneficial ownership stood at 44,194 shares held directly. The second transaction covered 5,341 shares at a weighted-average sale price of $36.619 per share, with individual trade prices ranging from $36.085 to $36.890, inclusive. After this second disposal, Juvenal's directly held beneficial ownership totaled 38,853 shares.

The filing was signed by Frank Stokes as attorney-in-fact on October 30, 2026. The filing notes that the reporting person undertakes to provide, upon request, full information regarding the number of shares and prices at which each transaction was effected to the SEC staff, the issuer, or a security holder of the issuer. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

Castle Biosciences CCO Tobin W Juvenal disclosed two sales of common stock on October 28, 2026, totaling 6,578 shares at weighted-average prices of $35.577 and $36.619, both under a 10b5-1 plan adopted May 28, 2026, leaving 38,853 shares held directly.